Cramer says Apple and Eli Lilly still have room to run after post-earnings rallies

Apple rose more than 4% after reporting second-quarter revenue of $111.2 billion, up 17% year over year and ahead of the $109.7 billion estimate, while issuing very strong guidance and highlighting an all-time high installed base above 2.5 billion devices. Eli Lilly added another 3% after a nearly 10% post-earnings jump Thursday, following a 56% revenue surge to $19.8 billion and what Jim Cramer called an extraordinary quarter. The S&P 500 set a fresh intraday high as enthusiasm around Apple and other Mag Seven names supported broader risk-on sentiment, while oil prices fell on renewed hopes of a peace agreement involving Iran and the United States.

Analysis

This tape is less about one-off beats and more about a reflexive re-rating of mega-cap duration assets. When the largest index weights simultaneously clear earnings and guidance hurdles, passive and factor flows can create a self-reinforcing squeeze: systematic trend, CTA, and risk-parity exposures all get nudged higher, which can keep a handful of names levitating even if breadth stays mediocre. The immediate second-order effect is pressure on under-owned large-cap defensives and cash-rich software/hardware suppliers that may now trade at a discount to growth despite similar balance-sheet quality.

Apple’s strength matters beyond the headline because it restores confidence in the consumer-tech install base as a monetization engine, not just a hardware cycle. That tends to lift the entire ecosystem: app monetizers, device accessory chains, and semiconductor names tied to premium device demand should benefit over the next 1-3 quarters if upgrade cycles and services attach rates hold. The main risk is that the market extrapolates too far from a single quarter into a full re-acceleration narrative; if the next handset/data-point disappoints, multiple compression could be abrupt because positioning has likely moved from skeptical to crowded in only a few sessions.

Lilly’s move is more interesting because it suggests investors are still underpricing the durability of GLP-1 capacity expansion and the knock-on effect on payer adoption. If the market starts treating this as a multi-year category winner rather than a one-quarter beat, then contract manufacturers, fill-finish capacity, and select obesity-adjacent suppliers may see a second leg higher. The contrarian risk is policy and supply normalization: any sign of pricing pressure, reimbursement pushback, or faster-than-expected competitive supply growth could cap upside once the initial momentum fades.

Key Decisions for Investors

• Stay long AAPL into the next 2-6 weeks, but use strength to sell upside calls against core stock if implied vol remains elevated; upside is still open, but the first-order move likely becomes a grind rather than a gap.
• Add to GOOGL/AMZN versus META/MSFT on a 1-3 month horizon; the market is rewarding clean monetization and better incremental confidence, while the laggards may remain range-bound until the next proof point.
• Initiate a long LLY / short large-cap pharma basket pair for 1-2 quarters; Lilly has the best odds of continuing to compound on execution, but size modestly because payer/policy headlines can reverse momentum quickly.
• Fade energy beta tactically over 1-4 weeks via short XLE or selective E&P underweights against long consumer/sensitive cyclicals; the trade works only if crude weakness persists and diplomatic headlines keep pressure on oil.